Literature DB >> 12692866

Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA.

Manuela Cappelletti1, Immacolata Zampaglione, Gabriella Rizzuto, Gennaro Ciliberto, Nicola La Monica, Elena Fattori.   

Abstract

BACKGROUND: Intramuscular gene delivery through injection of plasmid DNA has long been considered a promising approach for safe and simple in vivo gene expression for vaccination and gene therapy purposes. Recently, intramuscular gene delivery has been improved by applying low-voltage electric pulses after plasmid injection, a procedure that has been variably called gene electro-transfer, in vivo electroporation or electrical stimulation. Different types of electrical treatments have been used with excellent results both in terms of transgene expression levels and immunization outcome. This approach, therefore, holds promise for safe gene delivery to animals and humans designed for non-viral gene therapy and DNA-based vaccination. The molecular mechanisms underlying this increment in transduction efficiency are, however, still unclear.
METHODS: Plasmid DNA status and kinetics following gene electro-transfer was analyzed by different methods (Southern analysis, Q-PCR and transformation into competent bacteria).
RESULTS: A large amount of plasmid DNA is degraded in the first 4 h post-injection, with or without electroporation; later, the amount of intramuscular plasmid DNA is higher in electroporated samples. On electroporation, plasmid is partially protected from degradation, presumably by its early compartmentalization into the nuclei of muscle cells.
CONCLUSIONS: By investigating the intracellular outcome and persistence of plasmid DNA following simple injection or gene electro-transfer we provide useful information on the mechanisms of plasmid entry and expression and underline some of the steps that could be taken to further improve this methodology. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692866     DOI: 10.1002/jgm.352

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  10 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  Distribution and expression of recombinant plasmid encoding chicken interleukin-2.

Authors:  Z Q You; L Yu; C Z Zhang; L Li; M J Lu; Z J Mao; Y Liu; W Y Chu
Journal:  Vet Res Commun       Date:  2006-12-20       Impact factor: 2.459

3.  cDNA immunization of mice with human thyroglobulin generates both humoral and T cell responses: a novel model of thyroid autoimmunity.

Authors:  Eric M Jacobson; Erlinda Concepcion; Kenneth Ho; Peter Kopp; Jussara Vono Toniolo; Yaron Tomer
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

4.  A novel minigene scaffold for therapeutic cancer vaccines.

Authors:  Luigi Aurisicchio; Arthur Fridman; Ansuman Bagchi; Elisa Scarselli; Nicola La Monica; Gennaro Ciliberto
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110

Review 5.  Gene Electrotransfer: A Mechanistic Perspective.

Authors:  Christelle Rosazza; Sasa Haberl Meglic; Andreas Zumbusch; Marie-Pierre Rols; Damijan Miklavcic
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391

Review 6.  A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle.

Authors:  Emilia Sokołowska; Agnieszka Urszula Błachnio-Zabielska
Journal:  Int J Mol Sci       Date:  2019-06-06       Impact factor: 5.923

7.  Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.

Authors:  Luigi Aurisicchio; Arthur Fridman; David Mauro; Rose Sheloditna; Alberto Chiappori; Ansuman Bagchi; Gennaro Ciliberto
Journal:  J Transl Med       Date:  2020-01-30       Impact factor: 5.531

8.  COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.

Authors:  Antonella Conforti; Emanuele Marra; Fabio Palombo; Giuseppe Roscilli; Micol Ravà; Valeria Fumagalli; Alessia Muzi; Mariano Maffei; Laura Luberto; Lucia Lione; Erika Salvatori; Mirco Compagnone; Eleonora Pinto; Emiliano Pavoni; Federica Bucci; Grazia Vitagliano; Daniela Stoppoloni; Maria Lucrezia Pacello; Manuela Cappelletti; Fabiana Fosca Ferrara; Emanuela D'Acunto; Valerio Chiarini; Roberto Arriga; Abraham Nyska; Pietro Di Lucia; Davide Marotta; Elisa Bono; Leonardo Giustini; Eleonora Sala; Chiara Perucchini; Jemma Paterson; Kathryn Ann Ryan; Amy-Rose Challis; Giulia Matusali; Francesca Colavita; Gianfranco Caselli; Elena Criscuolo; Nicola Clementi; Nicasio Mancini; Rüdiger Groß; Alina Seidel; Lukas Wettstein; Jan Münch; Lorena Donnici; Matteo Conti; Raffaele De Francesco; Mirela Kuka; Gennaro Ciliberto; Concetta Castilletti; Maria Rosaria Capobianchi; Giuseppe Ippolito; Luca G Guidotti; Lucio Rovati; Matteo Iannacone; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

9.  Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

Authors:  Claudia Marcela Diaz; Alberto Chiappori; Luigi Aurisicchio; Ansuman Bagchi; Jason Clark; Sheri Dubey; Arthur Fridman; Jesus C Fabregas; John Marshall; Elisa Scarselli; Nicola La Monica; Gennaro Ciliberto; Alberto J Montero
Journal:  J Transl Med       Date:  2013-03-08       Impact factor: 5.531

10.  Emerging cancer vaccines: the promise of genetic vectors.

Authors:  Luigi Aurisicchio; Gennaro Ciliberto
Journal:  Cancers (Basel)       Date:  2011-09-22       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.